Probiotics-related Clostridium butyricum bacteraemia after COVID-19, confirmed by whole-genome sequencing

Yuya Kawamoto, Masahiro Suzuki, Mitsunaga Iwata, Yuki Uehara

研究成果: ジャーナルへの寄稿学術論文査読

抄録

A man in his 70s was admitted to an intensive care unit with severe COVID-19 and treated with dexamethasone and tocilizumab. After recovery from COVID-19, he developed Clostridium butyricum bacteraemia and non-occlusive mesenteric ischaemia, with fatal outcome. He had been prescribed C. butyricum MIYAIRI 588 fine granules as probiotics for a month. The genome sequences of the C. butyricum isolate from the blood culture and C. butyricum MIYAIRI 588 fine granules were identical by single nucleotide polymorphism analysis. This is the first case of definitive probiotics-related C. butyricum bacteraemia after treatment of severe COVID-19.

本文言語英語
ジャーナルBMJ Case Reports
17
8
DOI
出版ステータス出版済み - 03-08-2024
外部発表はい

All Science Journal Classification (ASJC) codes

  • 医学一般

フィンガープリント

「Probiotics-related Clostridium butyricum bacteraemia after COVID-19, confirmed by whole-genome sequencing」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル